Steven Lichtman
Stock Analyst at Oppenheimer
(3.07)
# 1,210
Out of 4,901 analysts
66
Total ratings
42.55%
Success rate
13.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Maintains: Outperform | $312 → $324 | $288.27 | +12.39% | 6 | May 9, 2025 | |
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $84.13 | +24.81% | 8 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $94.22 | +43.28% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $3.96 | +203.03% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $86.92 | +26.55% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $89.78 | +4.70% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $7.28 | +792.86% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $15.75 | +268.25% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $12.14 | -9.35% | 5 | May 9, 2024 | |
| ANGO AngioDynamics | Upgrades: Outperform | $12 | $8.60 | +39.53% | 2 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $87 | $83.95 | +3.63% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $58 → $68 | $103.19 | -34.10% | 2 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $0.74 | +374.38% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $390.87 | -26.32% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $98.50 | +6.60% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $17.09 | +777.71% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $72.70 | +16.92% | 3 | Sep 4, 2020 |
Insulet
May 9, 2025
Maintains: Outperform
Price Target: $312 → $324
Current: $288.27
Upside: +12.39%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $84.13
Upside: +24.81%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $94.22
Upside: +43.28%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $3.96
Upside: +203.03%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $86.92
Upside: +26.55%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $89.78
Upside: +4.70%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $7.28
Upside: +792.86%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $15.75
Upside: +268.25%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $12.14
Upside: -9.35%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $8.60
Upside: +39.53%
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $83.95
Upside: +3.63%
Feb 1, 2024
Maintains: Perform
Price Target: $58 → $68
Current: $103.19
Upside: -34.10%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $0.74
Upside: +374.38%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $390.87
Upside: -26.32%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $98.50
Upside: +6.60%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $17.09
Upside: +777.71%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $72.70
Upside: +16.92%